Infectious Disease

Antimicrobial programs, which need to be closely connected to infection control programs and clinical microbiology labs, are playing an emerging role in slowing the spread of methicillin-resistant Staphylococcus aureus.

Concerns about methicillin-resistant Staphylococcus aureus (MRSA) infection skyrocketed in 2000, when its prevalence in the US dramatically increaseed. One key to fighting MRSA is preventing its transmission.

Methicillin-resistant Staphylococcus aureus (MRSA) infections are becoming more common in hospitals and health care facilities and have still higher incidence rates in nursing homes and long-term-care facilities. Listen here for valuable information on MRSA prevention and treatment.

Screening is thought by many to play a key role in reducing the incidence of methicillin-resistant Staphylococcus aureus infection, but some argue that it isn't always necessary.

Guidelines from organizations such as the Infectious Disease Society of North America play a key role in the treatment of methicillin-resistant Staphylococcus aureus and can help determine which therapies work best for which patients.

When treating methicillin-resistant Staphylococcus aureus infection, some clinicians have argued that newer, costlier drugs can save money if used from the beginning in place of older, cheaper alternatives.